Lyell Immunopharma vs Vivtex
Side-by-side comparison of AI visibility scores, market position, and capabilities
Lyell Immunopharma develops next-generation CAR-T cell therapies designed to overcome T cell exhaustion and treat solid tumors, the frontier of cell therapy.
About
Lyell Immunopharma is a clinical-stage cell therapy company founded in 2018 by Rick Klausner and publicly traded on Nasdaq. The company focuses on next-generation CAR-T therapies that address the key limitations of first-generation products, particularly the exhaustion and dysfunction of engineered T cells that limits efficacy especially against solid tumors. Lyell has developed proprietary T cell reprogramming technologies including gene overexpression approaches that maintain T cell stemness and fitness during manufacturing and after infusion. The company is applying these technologies to both hematological malignancies and solid tumors in a pipeline of clinical programs. Lyell has established a research collaboration with GlaxoSmithKline to combine cell therapy expertise. While first-generation CAR-T products have demonstrated remarkable responses in blood cancers, Lyell is focused on the much larger unmet need in solid tumors where current CAR-T therapies have shown limited efficacy. The company represents the scientific evolution of the cell therapy field toward more durable and broadly applicable treatments.
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.
About
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.